Clinical Cell Biology and FACS Core Unit
Assoc. Prof. René Geyeregger, PhD
Groupleader emeritus: Assoc. Prof. Gerhard Fritsch, PhD
Postdoctoral Fellows: Wolfgang Paster, PhD
Diploma/MSc Student: Sandra Sonderegger, BSc
Technicians: Christine Hofmann-Freimüller, MSc l Ing. Dieter Printz l Daniela Scharner l Julia Stemberger l Dijana Trbojevic l Elke Zipperer l DI (FH) Angela Halfmann
Flow cytometry and GMP-compliance work as a supportive interface between research and therapy.
Most of our work consists of doing diagnostics and providing cytometric cell analyses and cell sorting services, primarily to the St. Anna Children’s Hospital, but also to other labs at the Children’s Cancer Research Institute (CCRI) as well as to external research institutes (mainly through the FACS Core Unit). Over the past years, the number of diagnostic applications has increased considerably and now also includes analyses that address spherocytosis and evaluate human sperm fertility. Every year, over 40,000 cytometric cell analyses and more than 2,000 cell sorts are carried out, the main purpose of these being to control the donor/recipient type of the different blood cells using FISH or PCR methods in post allo-transplantation patients.
Extensive internal quality control mechanisms are in place, which conform to internal standard operating procedures (SOPs). In addition, we participate in the regular Austrian and German quality control trials, organized by ÖQUASTA (Austrian Society for Quality Assurance and Standardization of Medical-Diagnostics) and INSTAND (Society for Promotion of Quality Assurance in Medical Laboratories). Our task here is to measure subtypes of blood leukocytes, stem cells, and residual leukocytes in blood products.
The second largest area contains clinical routine and concerns the manipulation of all cells or blood products that are administered to patients as part of their treatment regimens. These procedures take place under sterile conditions in our GMP laboratory.
After successful validation of the system in 2010, we were able to introduce a new freezing medium for the storage of patient cells. The preparation of MNC for clinical use in extracorporeal photopheresis ("mini ECP") proved extraordinarily successful for treatment of Graft-versus-host disease (GVHD) in very young patients. All these procedures do of course require the certification of the laboratory by the AGES according to the tissue safety act (Gewebesicherheitsgesetz) and medicinal product act (Arzneimittelgesetz); they were first approved in 2010 and recently renewed in July 2017.
Clinical phase I/II study of novel T-cell-based immunotherapy
Viral infections are among the most frequent and life-threatening complications following hematopoietic stem cell transplantation (HSCT), especially in paediatric patients. Therefore, our research focus is mainly on the development of novel T-cell-based immunotherapies for the treatment of virus-associated malignancies in patients after HSCT. Based on our novel and fast method for the manufacture of virus-specific T-cells, we initiated a clinical phase I/II trial VISIT (Virus-Specific ImmunoTherapy), which was approved by the AGES in July 2016 and funded by the ZIT Life Science Call (Wirtschaftsagentur).
Our group aims at developing new tests and methods for routine laboratory or clinical applications. Presently, our research interests are focused on the extension of virus-specific T-cell products against Epstein-Barr-Virus (EBV) and Polyomavirus (BKV). More detailed information on the process of engraftment and immune reconstitution (IR) of patients after HSCT will also help to better identify patients at risk for transplant related side effects. For this reason, we are continuously expanding our 10 color flow cytometric assays to >14 colors in order to additionally measure different subtypes of CD34+ hematopoietic stem- and progenitor cells, T-cells, B-cells, NK-cells, monocytes and dendritic cells.
FACS Core Unit
For more detailed information about the René Geyeregger´s group and its services please visit the section FACS Core Unit.
Tischer S, Geyeregger R, Kwoczek J, Heim A, Figueiredo C, Blasczyk R, Maecker-Kolhoff B, Eiz-Vesper B. Discovery of immunodominant T-cell epitopes reveals penton protein as a second immunodominant target in human adenovirus infection. J Transl Med. 2016;14(1):286.
Dmytrus J, Matthes-Martin S, Pichler H, Worel N, Geyeregger R, Frank N, Frech C, Fritsch G. Multi-color immune-phenotyping of CD34 subsets reveals unexpected differences between various stem cell sources. Bone Marrow Transplant. 2016;51(8):1093-1100.
Freimuller C, Stemberger J, Artwohl M, Germeroth L, Witt V, Fischer G, Tischer S, Eiz-Vesper B, Knippertz I, Dorrie J, Schaft N, Lion T, Fritsch G, Geyeregger R. Selection of adenovirus-specific and Epstein-Barr virus-specific T cells with major histocompatibility class I streptamers under Good Manufacturing Practice (GMP)-compliant conditions. Cytotherapy. 2015;17(7):989-1007.
Geyeregger R, Freimuller C, Stemberger J, Fischer G, Witt V, Fritsch G. Human AdV-specific T cells: persisting in vitro functionality despite lethal irradiation. Bone Marrow Transplant. 2014;49(7):934-941.
Geyeregger R, Freimuller C, Stemberger J, Artwohl M, Witt V, Lion T, Fischer G, Lawitschka A, Ritter J, Hummel M, Holter W, Fritsch G, Matthes-Martin S. First-in-man clinical results with good manufacturing practice (GMP)-compliant polypeptide-expanded adenovirus-specific T cells after haploidentical hematopoietic stem cell transplantation. J Immunother. 2014;37(4):245-249.
Dorrie J, Krug C, Hofmann C, Muller I, Wellner V, Knippertz I, Schierer S, Thomas S, Zipperer E, Printz D, Fritsch G, Schuler G, Schaft N, Geyeregger R. Human adenovirus-specific gamma/delta and CD8+ T cells generated by T-cell receptor transfection to treat adenovirus infection after allogeneic stem cell transplantation. PLoS One. 2014;9(10):e109944.
Geyeregger R, Freimuller C, Stevanovic S, Stemberger J, Mester G, Dmytrus J, Lion T, Rammensee HG, Fischer G, Eiz-Vesper B, Lawitschka A, Matthes S, Fritsch G. Short-term in-vitro expansion improves monitoring and allows affordable generation of virus-specific T-cells against several viruses for a broad clinical application. PLoS One. 2013;8(4):e59592.